---
title: 'End points and Outcomes in Follicular Lymphoma: What should we measure, how,
  and why?'
date: '2025-02-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40019453/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250301170923&v=2.18.0.post9+e462414
source: Blood
description: Overall survival (OS) and quality of life (QoL) are clinically relevant
  outcomes/endpoints during examination of therapies. However, with median OS approaching
  20 years for patients with follicular lymphoma (FL), it is often not feasible to
  use OS as a primary endpoint in clinical studies. While validated tools for assessing
  QoL in patient with lymphoma exist, QoL data are rarely the sole basis for drug
  approvals in FL. Therefore, other survival endpoints, surrogates, and intermediate
  ...
disable_comments: true
---
Overall survival (OS) and quality of life (QoL) are clinically relevant outcomes/endpoints during examination of therapies. However, with median OS approaching 20 years for patients with follicular lymphoma (FL), it is often not feasible to use OS as a primary endpoint in clinical studies. While validated tools for assessing QoL in patient with lymphoma exist, QoL data are rarely the sole basis for drug approvals in FL. Therefore, other survival endpoints, surrogates, and intermediate ...